Blaese RM - Search Results

1

Amphotropic murine leukemia retrovirus is not an acute pathogen for primates.

Cornetta K, Moen RC, Culver K, Morgan RA, McLachlin JR, Sturm S, Selegue J, London W, Blaese RM, Anderson WF. Cornetta K, et al. Among authors: blaese rm. Hum Gene Ther. 1990 Spring;1(1):15-30. doi: 10.1089/hum.1990.1.1-15. Hum Gene Ther. 1990. PMID: 1964393

2

Infection of human cells with murine amphotropic replication-competent retroviruses.

Cornetta K, Nguyen N, Morgan RA, Muenchau DD, Hartley JW, Blaese RM, Anderson WF. Cornetta K, et al. Among authors: blaese rm. Hum Gene Ther. 1993 Oct;4(5):579-88. doi: 10.1089/hum.1993.4.5-579. Hum Gene Ther. 1993. PMID: 8280796

3

Lymphocyte gene therapy.

Culver KW, Anderson WF, Blaese RM. Culver KW, et al. Among authors: blaese rm. Hum Gene Ther. 1991 Summer;2(2):107-9. doi: 10.1089/hum.1991.2.2-107. Hum Gene Ther. 1991. PMID: 1911929 Clinical Trial.

4

In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys.

Culver KW, Morgan RA, Osborne WR, Lee RT, Lenschow D, Able C, Cornetta K, Anderson WF, Blaese RM. Culver KW, et al. Among authors: blaese rm. Hum Gene Ther. 1990 Winter;1(4):399-410. doi: 10.1089/hum.1990.1.4-399. Hum Gene Ther. 1990. PMID: 1964096

5

Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector.

Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Mullen CA, et al. Among authors: blaese rm. Hum Gene Ther. 1996 Jun 10;7(9):1123-9. doi: 10.1089/hum.1996.7.9-1123. Hum Gene Ther. 1996. PMID: 8773514

6

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P, et al. Rosenberg SA, et al. Among authors: blaese rm. Hum Gene Ther. 1996 Dec 1;7(18):2287-313. doi: 10.1089/hum.1996.7.18-2287. Hum Gene Ther. 1996. PMID: 8953320 No abstract available.

7

A simple and reliable method for screening retroviral producer clones without selectable markers.

Onodera M, Yachie A, Nelson DM, Welchlin H, Morgan RA, Blaese RM. Onodera M, et al. Among authors: blaese rm. Hum Gene Ther. 1997 Jul 1;8(10):1189-94. doi: 10.1089/hum.1997.8.10-1189. Hum Gene Ther. 1997. PMID: 9215736

8

Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients.

Jensen TG, Sullivan DM, Morgan RA, Taichman LB, Nussenblatt RB, Blaese RM, Csaky KG. Jensen TG, et al. Among authors: blaese rm. Hum Gene Ther. 1997 Nov 20;8(17):2125-32. doi: 10.1089/hum.1997.8.17-2125. Hum Gene Ther. 1997. PMID: 9414260

9

Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent.

Springett GM, Moen RC, Anderson S, Blaese RM, Anderson WF. Springett GM, et al. Among authors: blaese rm. J Virol. 1989 Sep;63(9):3865-9. doi: 10.1128/JVI.63.9.3865-3869.1989. J Virol. 1989. PMID: 2788225 Free PMC article.

10

The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990.

Anderson WF, Blaese RM, Culver K. Anderson WF, et al. Among authors: blaese rm. Hum Gene Ther. 1990 Fall;1(3):331-62. doi: 10.1089/hum.1990.1.3-331. Hum Gene Ther. 1990. PMID: 11642817 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

242 results

Search Page